Axonics - AXNX Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings or view top-rated stocks.

8 brokers have issued 1-year target prices for Axonics' stock. Their AXNX share price forecasts range from $69.00 to $90.00. On average, they predict the company's share price to reach $79.00 in the next year. This suggests a possible upside of 41.5% from the stock's current price.
View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts.

Axonics' stock was trading at $62.53 at the beginning of the year. Since then, AXNX shares have decreased by 10.7% and is now trading at $55.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AXNX earnings forecast.

Axonics, Inc. (NASDAQ:AXNX) posted its earnings results on Wednesday, March, 1st. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.24. The company earned $85.90 million during the quarter, compared to the consensus estimate of $84.14 million. Axonics had a negative trailing twelve-month return on equity of 11.82% and a negative net margin of 21.81%. The company's revenue was up 61.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.34) EPS.

ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Neuberger Berman Disrupters ETF (NBDS), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust US Equity Opportunities ETF (FPX) and Principal Healthcare Innovators ETF (BTEC).

Axonics updated its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$342.00 million, compared to the consensus revenue estimate of $336.36 million.

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Axonics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bamco Inc. NY (3.58%), Lord Abbett & CO. LLC (3.37%), Norges Bank (2.47%), Credit Suisse AG (1.94%), Fred Alger Management LLC (1.86%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends.

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXNX stock can currently be purchased for approximately $55.82.

Axonics (NASDAQ:AXNX) has a market capitalization of $2.79 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

The company employs 517 workers across the globe.

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321.